Nonprimary pT1 Nonmuscle Invasive Bladder Cancer Treated With Bacillus Calmette-Guerin is Associated With Higher Risk of Progression Compared to Primary T1 Tumors

Journal of Urology

Volumn 184, Issue 1, 2010, Pages 81-86

  Alkhateeb, Sultan S ^a   Van Rhijn, Bas W G ^a   Finelli, Antonio ^a   van der Kwast, Theodorus ^b   Evans, Andrew ^b   Hanna, Sally ^a   Vajpeyi, Rati ^a   Fleshner, Neil E ^a   Jewett, Michael A S ^a   Zlotta, Alexandre R ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

BCG vaccine; disease progression; mortality; recurrence; urinary bladder neoplasms

Indexed keywords

BCG VACCINE;

AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENDER; HUMAN; INFORMATION; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PATHOLOGY; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RISK; SURVIVAL RATE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

AGED; BCG VACCINE; CARCINOMA IN SITU; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 77953123512     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.03.022     Document Type: Article

References (16)

1. Saint F., Salomon L., Quintela R., et al. Do prognostic parameters of remission versus relapse after bacillus Calmette-Guerin (BCG) immunotherapy exist?. Analysis of a quarter century of literature. Eur Urol 43 (2003) 351
2. Losa A., Hurle R., and Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 163 (2000) 68
3. Takashi M., Wakai K., Hattori T., et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ. Int Urol Nephrol 33 (2002) 41
4. Hurle R., Losa A., Manzetti A., et al. Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54 (1999) 258
5. Fernandez-Gomez J., Solsona E., Unda M., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53 (2008) 992
6. Akaza H., Hinotsu S., Aso Y., et al. Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 75 (1995) 552
7. Torrence R.J., Kavoussi L.R., Catalona W.J., et al. Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. J Urol 139 (1988) 941
8. Cookson M.S., and Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 148 (1992) 797
9. Pansadoro V., Emiliozzi P., de Paula F., et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 59 (2002) 227
10. Okamura T., Tozawa K., Yamada Y., et al. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer. J Urol 156 (1996) 967
11. Schrier B.P., Hollander M.P., van Rhijn B.W., et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292
12. El-Abbady A.A., Shoukry M.S., Hanno A.G., et al. Repeated transurethral resection of recurrent superficial bladder tumors-does it affect the spread and stage of the tumor?. Scand J Urol Nephrol 36 (2002) 60
13. Cheng L., Neumann R.M., Weaver A.L., et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens. Am J Clin Pathol 113 (2000) 275
14. Dutta S.C., Smith Jr. J.A., Shappell S.B., et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 (2001) 490
15. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163 (2000) 73
16. Sylvester R.J., van derMeijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466